Segelmark L, et al. - Researchers herein estimated, and investigated the potential risk factors for severe infections in ANCA-associated vasculitis (AAV) patients treated with rituximab (RTX), an anti-CD20 antibody that selectively depletes B-cells, at rheumatology clinics in Mexico City, Mexico and Lund, Sweden. In this retrospective case-record review (2005–2015), included were 46 patients with AAV in Mexico City (n = 20) and Lund (n = 26) treated with RTX. Observations revealed a common occurrence of severe infections following RTX treatment, and mortality due to infection is a major concern. Occurrence of most severe infections was observed within the first year of treatment. They noted a negative correlation between ENT involvement and severe infection, which might indicate GPA phenotype heterogeneity. An independent predictive value of older age at time of RTX treatment for severe infections was identified.